CGA
SLS icon

Crescent Grove Advisors’s SELLAS Life Sciences SLS Stock Holding History

Crescent Grove Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-80
Closed -$31K – 156
2017
Q4 		$31K Hold
80
– – 0.01% 142
2017
Q3 		$42K Buy
80
+13
+19% +$8.58K 0.01% 140
2017
Q2 		$58K Buy
+67
New +$58.3K 0.02% 142

Other funds holding SLS

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Crescent Grove Advisors's SLS Position: Q1 2018 in Review

Crescent Grove Advisors sold out of SELLAS Life Sciences (SLS) in Q1 2018, closing a stake of 80 shares — an estimated $31K sold.

Crescent Grove Advisors first reported a position in SLS in Q2 2017 and held it in 3 quarters. The position peaked at $58K in Q2 2017. 16 funds tracked by Wall St. Rank hold SLS as of Q1 2018.

  • Crescent Grove Advisors reported no remaining SELLAS Life Sciences position as of Q1 2018 after selling out during the quarter.
  • Crescent Grove Advisors sold 80 SELLAS Life Sciences shares in Q1 2018, an estimated $31K.
  • Crescent Grove Advisors first reported a position in SELLAS Life Sciences in Q2 2017 and held it in 3 quarters.
  • Crescent Grove Advisors's SELLAS Life Sciences position peaked at $58K in Q2 2017.
  • 16 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2018.

Based on Crescent Grove Advisors's 13F filing for Q1 2018, filed 3 May 2018.